摘要
Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: Human stom- ach neoplasms model was established in nude mice. The nude mice were divided into control group, moderate-dose of rhGH group, low-dose rhGH group, 5-FU group, moderate-dose rhGH/5-FU group, and low-dose rhGH/5-FU group. The results of each group were observed after ten days. Results: After therapy, the body mass of rhGH groups was significantly increased compared with control group (P<0.05), the body mass of rhGH/5-FU groups was significantly increased compared with 5-FU group (P<0.05), but it was no significant difference between rhGH/5-FU groups and control group (P>0.05). The average tumor mass and volume of rhGH groups were not significantly increased compared with control group (P>0.05), but they were significantly reduced in 5-FU group and rhGH/5-FU groups (P<0.05). They were no significant difference between rhGH/5- FU groups and 5-FU group (P>0.05). After treatment, the percentages of S, G0/G1 and G2/M phases and proliferation index (PI) were not significantly changed in rhGH groups compared with control group (P>0.05), and the same with rhGH/5-FU groups compared with 5-FU group (P>0.05). The difference caused by dose of rhGH was not significant. Conclusion: rhGH enhances body mass, does not stimulate tumor growth, and has no adverse effects on tumor bearing nude mice. Combined with flurouracil, rhGH does not influence the efficacy of chemotherapy, and has no effect on tumor cell cycle kinetics.
Objective： To investigate the effect of different doses of recombined growth hormone （rhGH） on stomach neoplasms implanted in nude mice, and its efficacy in combining with chemotherapy （flurouracil, 5-FU）. Methods： Human stomach neoplasms model was established in nude mice. The nude mice were divided into control group, moderate-dose of rhGH group, low-dose rhGH group, 5-FU group, moderate-dose rhGH/5-FU group, and low-dose rhGH/5-FU group. The results of each group were observed after ten days. Results： After therapy, the body mass of rhGH groups was significantly increased compared with control group （P〈0.05）, the body mass of rhGH/5-FU groups was significantly increased compared with 5-FU group （P〈0.05）, but it was no significant difference between rhGH/5-FU groups and control group （P〉0.05）. The average tumor mass and volume of rhGH groups were not significantly increased compared with control group （P〉0.05）, but they were significantly reduced in 5-FU group and rhGH/5-FU groups （P〈0.05）. They were no significant difference between rhGH/5- FU groups and 5-FU group （P〉0.05）. After treatment, the percentages of S, G0/G1 and G2/M phases and proliferation index （PI） were not significantly changed in rhGH groups compared with control group （P〉0.05）, and the same with rhGH/5-FU groups compared with 5-FU group （P〉0.05）. The difference caused by dose of rhGH was not significant. Conclusion： rhGH enhances body mass, does not stimulate tumor growth, and has no adverse effects on tumor bearing nude mice. Combined with flurouracil, rhGH does not influence the efficacy of chemotherapy, and has no effect on tumor cell cycle kinetics.
